

World Journal of *Gastroenterology*

World J Gastroenterol 2024 March 7; 30(9): 994-1260



EDITORIAL

- 994 Role of exosomal circular RNAs as microRNA sponges and potential targeting for suppressing hepatocellular carcinoma growth and progression
Papadopoulos N, Trifylli EM
- 999 Role of albumin-bilirubin score in non-malignant liver disease
Xu SX, Yang F, Ge N, Guo JT, Sun SY
- 1005 Early prediction and prevention of infected pancreatic necrosis
Lv C, Zhang ZX, Ke L
- 1011 Impact of microplastics and nanoplastics on liver health: Current understanding and future research directions
Chiang CC, Yeh H, Shiu RF, Chin WC, Yen TH

GUIDELINES

- 1018 National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
Dar FS, Abbas Z, Ahmed I, Atique M, Aujla UI, Azeemuddin M, Aziz Z, Bhatti ABH, Bangash TA, Butt AS, Butt OT, Dogar AW, Farooqi JI, Hanif F, Haider J, Haider S, Hassan SM, Jabbar AA, Khan AN, Khan MS, Khan MY, Latif A, Luck NH, Malik AK, Rashid K, Rashid S, Salih M, Saeed A, Salamat A, Tayyab GUN, Yusuf A, Zia HH, Naveed A

REVIEW

- 1043 Diseases of bile duct in children
Eiamkulbutr S, Tubjareon C, Sanpavat A, Phewplung T, Srisan N, Sintusek P
- 1073 From liver to hormones: The endocrine consequences of cirrhosis
Quiroz-Aldave JE, Gamarra-Osorio ER, Durand-Vásquez MDC, Rafael-Robles LDP, Gonzáles-Yovera JG, Quispe-Flores MA, Concepción-Urteaga LA, Román-González A, Paz-Ibarra J, Concepción-Zavaleta MJ

MINIREVIEWS

- 1096 Prediction, prevention and management of gastroesophageal reflux after per-oral endoscopic myotomy: An update
Nabi Z, Inavolu P, Duvvuru NR

ORIGINAL ARTICLE

Clinical Trials Study

- 1108 Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China
Yang YY, Li KM, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Zhang LJ, Zheng HX, Xing XB, Wang LJ, Zuo XL, Ding SG, Lin R, Chen CX, Wang XW, Li JN

- 1121** Detachable string magnetically controlled capsule endoscopy for the noninvasive diagnosis of esophageal diseases: A prospective, blind clinical study

Yang YL, Qin HW, Chen ZY, Fan HN, Yu Y, Da W, Zhu JS, Zhang J

- 1132** Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity?

Gravina AG, Panarese I, Trotta MC, D'Amico M, Pellegrino R, Ferraraccio F, Galdiero M, Alfano R, Grieco P, Federico A

Observational Study

- 1143** Double-nylon purse-string suture in closing postoperative wounds following endoscopic resection of large (≥ 3 cm) gastric submucosal tumors

Wang SS, Ji MY, Huang X, Li YX, Yu SJ, Zhao Y, Shen L

- 1154** Recent trends in the epidemiology and clinical outcomes of inflammatory bowel disease in South Korea, 2010-2018

Kim S, Lee HJ, Lee SW, Park S, Koh SJ, Im JP, Kim BG, Han KD, Kim JS

Prospective Study

- 1164** Staging liver fibrosis with various diffusion-weighted magnetic resonance imaging models

Jiang YL, Li J, Zhang PF, Fan FX, Zou J, Yang P, Wang PF, Wang SY, Zhang J

- 1177** sTREM-1 as promising prognostic biomarker for acute-on-chronic liver failure and mortality in patients with acute decompensation of cirrhosis

Yu SM, Li H, Deng GH, Wang XB, Zheng X, Chen JJ, Meng ZJ, Zheng YB, Gao YH, Qian ZP, Liu F, Lu XB, Shi Y, Shang J, Chen RC, Huang Y

Basic Study

- 1189** Uridine diphosphate glucuronosyltransferase 1A1 prevents the progression of liver injury

Jiang JL, Zhou YY, Zhong WW, Luo LY, Liu SY, Xie XY, Mu MY, Jiang ZG, Xue Y, Zhang J, He YH

SYSTEMATIC REVIEWS

- 1213** Treatment of *Helicobacter pylori* with potassium competitive acid blockers: A systematic review and meta-analysis

Kanu JE, Soldera J

SCIENTOMETRICS

- 1224** Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis

Li HY, Zheng LL, Hu N, Wang ZH, Tao CC, Wang YR, Liu Y, Aizimuaji Z, Wang HW, Zheng RQ, Xiao T, Rong WQ

CASE REPORT

- 1237** PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report

Kong YH, Xu ML, Zhang JJ, Chen GQ, Hong ZH, Zhang H, Dai XX, Ma YF, Zhao XR, Zhang CY, Chen RZ, Xing PF, Zhang LY

LETTER TO THE EDITOR

- 1250** Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective
Huang JG
- 1253** Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis
Colapietro F, Pugliese N, Voza A, Aghemo A, De Nicola S
- 1257** Exploring non-curative endoscopic submucosal dissection: Current treatment optimization and future indication expansion
Zhu YN, Yuan XL, Liu W, Zhang YH, Mou Y, Hu B, Ye LS

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Pal Miheller, MD, PhD, Assistant Professor, Department of Surgery, Transplantation and Gastroenterology, Head of Gastroenterology, Semmelweis University, Budapest H-1088, Pest, Hungary. miheller.pal@semmelweis.hu

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Hua-Ge Yu*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

March 7, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/gerinfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/gerinfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/gerinfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER's OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Role of exosomal circular RNAs as microRNA sponges and potential targeting for suppressing hepatocellular carcinoma growth and progression

Nikolaos Papadopoulos, Eleni-Myrto Trifylli

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Zheng Y, China

Received: November 29, 2023

Peer-review started: November 29, 2023

First decision: December 26, 2023

Revised: January 3, 2024

Accepted: February 18, 2024

Article in press: February 18, 2024

Published online: March 7, 2024



Nikolaos Papadopoulos, The Second Department of Internal Medicine, 401 General Army Hospital of Athens, Athens 11525, Greece

Eleni-Myrto Trifylli, The First Department of Internal Medicine, 417 Share Army Fund Hospital, Athens 11521, Greece

Corresponding author: Nikolaos Papadopoulos, MD, PhD, Doctor, The Second Department of Internal Medicine, 401 General Army Hospital of Athens, 138 Mesogeion Ave, Athens 11525, Greece. nipapmed@gmail.com

Abstract

In this editorial, we comment on the article by Lyu *et al* published in the recent issue of the *World Journal of Gastroenterology* (2023; 2219-2840). Hepatocellular carcinoma (HCC) is a frequently encountered and highly aggressive primary liver cancer, which remains the third-commonest cause of cancer-related death despite the current therapeutic modalities. There is urgency in developing novel therapeutic approaches, such as by manipulating extracellular vesicles, which constitute a highly heterogeneous nanoparticle population that contains various cargoes. These cargoes have a pivotal role in cell-to-cell communication and can modify the functional level of the recipient cells *via* their uptake by other recipient cells. Exosomal non-coding RNAs have particular evolving significance in HCC, such as circular RNAs, which have been found differentially expressed in normal hepatic and HCC tissues. The aberrations in their expression levels have a key role in the HCC development and progression and the overall prognosis. In this editorial, we will shed light on the emerging role of exosomal circular RNAs in HCC development and progression, focusing on the oncogenic or potentially tumor suppressive effect of mesenchymal stem cells-derived exosomal non-coding RNAs.

Key Words: Exosomes; Hepatocellular carcinoma; Non-coding RNAs; Circular RNA; Tumor microenvironment; Anti-tumor immunity; Mesenchymal stem cells

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This paper sheds light on the role of exosomal circular RNAs as microRNA sponges and their potential targeting for suppressing hepatocellular carcinoma growth and progression.

Citation: Papadopoulos N, Trifylli EM. Role of exosomal circular RNAs as microRNA sponges and potential targeting for suppressing hepatocellular carcinoma growth and progression. *World J Gastroenterol* 2024; 30(9): 994-998

URL: <https://www.wjgnet.com/1007-9327/full/v30/i9/994.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i9.994>

INTRODUCTION

Hepatocellular carcinoma (HCC) is a frequently encountered and highly aggressive primary liver cancer, characterized by a high number of cancer-related deaths worldwide, constituting the third most common cause of cancer-related death [1]. Despite the novelties in the diagnostic and therapeutic strategies, including immunochemotherapy, targeted and local treatments, radiotherapy, and surgical approaches, the overall survival of HCC patients remains low due to chemoresistance and tumor recurrence[2]. There is a call for the discovery and development of novel therapeutic approaches, with the understanding of the molecular complexity of this malignancy being pivotal. The role of extracellular vesicles (EVs) and non-coding RNA molecules and their implications in HCC development and progression are in the spotlight of their ongoing studies, aiming to discover novel therapeutic targets and strategies[3].

EVs constitute a highly heterogeneous population of nanostructures composed of a lipid membrane (lipid bilayer) with several enclosed cargoes[4]. Their heterogeneity is attributed to their various sizes, biogenetic mechanisms, and the diversity of their cargoes, including coding or non-coding RNA molecules, proteins, lipids, several ligands, DNA molecules, and autophagosomes. A wide variety of cells can produce these vesicles *via* different mechanisms, including the inward or outward budding of the cell membrane or apoptosis, which lead to exosome, microvesicle, and apoptotic body generation, respectively[5]. The main classification of EVs is based on their size, including: (1) Exosomes; (2) microvesicles; and (3) apoptotic bodies, being the smallest (40-150 nm), medium-sized (150-1000 nm), and largest (> 1000 nm) subclass, respectively.

However, there is also another classification based on their biogenetic mechanism, including exosomes and ectosomes, with the former being produced by the integration of the multivesicular body (MVB) with the plasma membrane and the exocytosis of exosomes, while the latter *via* plasma membrane budding[6].

Focusing on the mechanism of exosome generation, the inward plasma membrane budding is primarily required, accompanied by the internalization of transmembrane proteins and the formation of vesicles. This process is followed by several distinct steps for the final generation and release of exosomes from the parental cell, including the formation of early endosomes and the maturation of early endosomes into late endosomes, which either lead to intraluminal vesicles (ILVs) *via* the invagination of the membrane of the latter or they are retransferred to the cell membrane. Afterward, the incorporation of ILVs will lead to MVBs, which are either destructed in lysosomes or fused with the cell membrane to release exosomes[7]. All the aforementioned biogenetic pathways are strictly orchestrated under the influence of endosomal sorting (ESCRT) complexes 0-III to modify and remodel the membrane and generate ILVs and, eventually, MVBs. Moreover, soluble NSF attachment protein receptor (SNARE) proteins are required for the MVB fusion with plasma membrane release of exosomes in the extracellular space (Figure 1)[8]. These nanostructures have a pivotal role in cell-to-cell communication, as they can modify the functional and transcriptional level of the recipient cells *via* the uptake of their cargoes. Meanwhile, their high biocompatibility, low immunogenicity, and their role in intercellular communication make them ideal drug delivery vectors or targets[9,10]. There is an increased interest in the role of exosomal non-coding circular RNAs (circRNAs) in HCC development and progression[11]. Advances in RNA sequencing have given new opportunities to identify several non-coding molecules, such as circRNAs. CircRNAs are found in abundance in eukaryote cells under physiological conditions. However, they are also closely related to several diseases, including cancer[12]. These molecules are biologically functional and can regulate gene expression. This phenomenon is implied by the fact that circRNAs can protect mRNA translation from microRNAs (miRNAs) that can silence the mRNA translation or lead to their degradation (miRNA “sponges”)[13]. Additionally, they can enhance the expression of several genes in the parental cells *via* interacting with polymerase II, interact with RNA-binding proteins, leading to significant alterations in the gene expression and translation, and alter protein locations[14] (Figure 2).

Several aberrations are observed in the circRNA expression levels in HCC tissue compared to physiological ones. The mechanisms on how circRNAs are implicated in HCC are still not adequately clear; however, their significant contribution cannot be doubted[15]. Taking advantage of their functions will open new horizons in the development of circRNA-centered therapeutic and diagnostic perspectives.

ROLE OF EXOSOMAL CIRCRNAS AS A THERAPEUTIC TOOL IN HCC

It is demonstrated that the role of circRNAs is dual in HCC, as they can either promote or suppress tumor progression *via* interacting with oncogenic or tumor-suppressive miRNAs. The aforementioned phenomenon is attributed to their role as a “sponge” for oncogenic miRNAs or tumor suppressive miRNAs, which can lead to tumor inhibition or promotion,




Figure 1 Biogenesis of extracellular vesicles. Exosome generation is initiated by the budding of the inward plasma membrane and the internalization of transmembrane proteins, forming early endosomes, which are further matured into late endosomes. Under the contribution of endosomal sorting complexes 0-III, the invagination of the late endosomal membrane forms the intraluminal vesicles (ILVs). Eventually, multivesicular bodies (MVBs), which have several ILVs in their lumen, are formed. Another site of cargo, besides the membrane, is the trans-Golgi complex or cytoplasm. Afterward, MVBs are either fused with cell membrane for the exocytosis of exosomes or degraded in lysosomes. However, they can form amphisomes *via* fusion with autophagosomes, which are either degraded in lysosomes or fuse with plasma membrane to release the vesicles into the extracellular space. A broad spectrum of cells/tissues, including mesenchymal stem cells, can produce extracellular vesicles. ILV: Intraluminal vesicles; MSC: Mesenchymal stem cells. Created with "BioRender.com" (Supplementary material)[20].

respectively[16]. There are several aberrations in the expression levels of circRNAs, which may lead to tumor growth and progression and generally poor prognosis or they can induce suppression of HCC development. The study by Lyu *et al* [17], which was published in the recent issue of *World Journal of Gastroenterology*, demonstrated the role of mesenchymal stem cells (MSCs)-derived exosomal hsa_circ_0000563 (circ-563) as a sponge for miR-148a-3p leading to tumor progression, whereas the silencing of circ-563 suppressed the HCC growth and development[17].

Exploring earlier studies, in the study by Zhang *et al*[18], tumor-suppressive miR-148a-3p was found to be downregulated in HCC tissue, compared to physiological hepatic tissue, which was associated with aggressive tumor behavior and worrisome prognosis[18]. Additionally, they observed that hepatic stellate cell (HSC)-derived exosomes, in which miR-148a-3p was depleted, led to HCC progression *via* the ITGA5/PI3K/Akt axis, which is involved in cell proliferation, migration, and survival, as well as in cancer development and drug resistance. However, the increased expression of exosomal miR-148a-3p in HCC tissue leads to tumor suppression[18].

Another study about the role of miR-148a-3p in HCC by Lyu *et al*[19] has demonstrated the interplay between the aforementioned miRNA and metal-regulatory transcription factor-1 (MTF-1) in HCC progression[19]. More specifically, MTF-1 is closely implicated in metal homeostasis, while its overexpression leads to hepatocarcinogenesis, tumor proliferation, and metastatic dissemination, as was demonstrated in conditions like copper exposure. Enhanced miR-148a-3p expression successfully suppressed HCC growth and progression that were induced *via* MTF-1. However, it was observed that exosomal miR-148a-3p was notably downregulated in HCC patients, whereas its enhanced expression led to suppression of MTF-1 and HCC inhibition[19].

Eventually, the development of RNA sequencing, the identification of circRNAs, and the development of the competitive endogenous RNA (ceRNA) theory expanded the research approaches for HCC pathogenesis and therapeutic targets. The ceRNA theory suggests that several RNA molecules like long non-coding RNA, circRNA, and mRNA can competitively share miRNA binding sites. In this recent study of Lyu *et al*[17], they also focused on the significant role of the tumor microenvironment (TME) in HCC, focusing on the implication of MSCs *via* releasing exosomes. MSCs are recruited in HCC TME, exerting various effects, including suppression of anti-tumor immunity, and promoting neoangiogenesis that favors tumor growth and progression. Additionally, they differentiate into stromal cells, enhancing the tumor stroma. They can also induce several signaling pathways *via* secreting cytokines and EVs, like exosomes. The manipulation of MSC-derived molecules like exosomes for modifying the functionality of the recipient cells through the delivery of anti-HCC agents or genetic modulatory molecules can potentially widen the therapeutic perspectives. In the aforementioned study, they utilized labeled isolated MSC-derived exosomes co-cultured with HCC. As demonstrated in the previous study by Lyu *et al*[19], overexpression of exosomal miR-148a-3p, which targets MTF-1, notably decreased HCC progression, whereas, in the present study, they reported that among the various circRNAs from the databases, has_circ563 had the most partially complementary sequence for miR-148a-3p[17]. In addition, they demonstrated a correlation between MTF-1 and circ563 overexpression, as well as a correlation between circ563 upregulation and




Figure 2 Role of circular RNA as “microRNA sponge”. After the active microRNA (miRNA) strand (leading strand/mature miRNA) is loaded on the RISC complex, the so-called miRISC (seed sequence), which is capable of binding on a target mRNA strand, leads in the suppression of mRNA translation, silencing, or even degradation. Circular RNAs (circRNAs) are non-coding RNA molecules that have a pivotal contribution to gene expression, as they can protect mRNA translation from miRNAs, *via* miRNA sponging, interact with several proteins, including RNA-binding proteins and polymerase II, and translocate them. circRNA: Circular RNAs; mRNA: Messenger RNA; miRs: MicroRNAs. Created with “BioRender.com” (Supplementary material)[20].

decreased miR-148-3p expression levels, implying its potential role as an “miRNA sponge” and eventually as an HCC promoter. On the other hand, silencing of circ-563 led to tumor suppression, suggesting its potential use as an anti-HCC therapeutic strategy[17].

CONCLUSION

New opportunities for HCC management could be opened up *via* the deep understanding of ceRNA theory, suggesting the role of circRNAs as “miRNA sponges”, accompanied by the utilization of exosomes as delivery vectors.

FOOTNOTES

Author contributions: Papadopoulos N designed the overall concept and outline of the manuscript; Trifylli EM contributed to the discussion and design of the manuscript; Papadopoulos N and Trifylli EM contributed to the writing and editing of the manuscript, illustrations, and review of the literature.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Greece

ORCID number: Nikolaos Papadopoulos 0000-0002-8702-1685; Eleni-Myrto Trifylli 0000-0002-0080-9032.

S-Editor: Chen YL

L-Editor: Wang TQ

P-Editor: Yuan YY

REFERENCES

- 1 **Rumgay H**, Arnold M, Ferlay J, Lesi O, Cabaasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. *J Hepatol* 2022; **77**: 1598-1606 [PMID: 36208844 DOI: 10.1016/j.jhep.2022.08.021]
- 2 **Reig M**, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol* 2022; **76**: 681-693 [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018]
- 3 **Kousta E**, Trifylli EM, Sarantis P, Papadopoulos N, Papanikolopoulos K, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Matthaios D, Karamouzis MV. An Insight into the Arising Role of MicroRNAs in Hepatocellular Carcinoma: Future Diagnostic and Therapeutic Approaches. *Int J Mol Sci* 2023; **24** [PMID: 37108330 DOI: 10.3390/ijms24087168]
- 4 **Akers JC**, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. *J Neurooncol* 2013; **113**: 1-11 [PMID: 23456661 DOI: 10.1007/s11060-013-1084-8]
- 5 **Willms E**, Cabañas C, Mäger I, Wood MJA, Vader P. Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression. *Front Immunol* 2018; **9**: 738 [PMID: 29760691 DOI: 10.3389/fimmu.2018.00738]
- 6 **Cocucci E**, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends Cell Biol* 2015; **25**: 364-372 [PMID: 25683921 DOI: 10.1016/j.tcb.2015.01.004]
- 7 **Han QF**, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, Zhang SJ. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. *Mol Cancer* 2022; **21**: 207 [PMID: 36320056 DOI: 10.1186/s12943-022-01671-0]
- 8 **Arya SB**, Collie SP, Parent CA. The ins-and-outs of exosome biogenesis, secretion, and internalization. *Trends Cell Biol* 2023 [PMID: 37507251 DOI: 10.1016/j.tcb.2023.06.006]
- 9 **Berumen Sánchez G**, Bunn KE, Pua HH, Rafat M. Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. *Cell Commun Signal* 2021; **19**: 104 [PMID: 34656117 DOI: 10.1186/s12964-021-00787-y]
- 10 **Meng W**, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. *Drug Deliv* 2020; **27**: 585-598 [PMID: 32264719 DOI: 10.1080/10717544.2020.1748758]
- 11 **Meng H**, Niu R, Huang C, Li J. Circular RNA as a Novel Biomarker and Therapeutic Target for HCC. *Cells* 2022; **11** [PMID: 35741077 DOI: 10.3390/cells11121948]
- 12 **Vo JN**, Cieslik M, Zhang Y, Shukla S, Xiao L, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, Robinson DR, Nesvizhskii AI, Chinnaiyan AM. The Landscape of Circular RNA in Cancer. *Cell* 2019; **176**: 869-881.e13 [PMID: 30735636 DOI: 10.1016/j.cell.2018.12.021]
- 13 **Jarlstad Olesen MT**, S Kristensen L. Circular RNAs as microRNA sponges: evidence and controversies. *Essays Biochem* 2021; **65**: 685-696 [PMID: 34028529 DOI: 10.1042/EBC20200060]
- 14 **Kristensen LS**, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet* 2019; **20**: 675-691 [PMID: 31395983 DOI: 10.1038/s41576-019-0158-7]
- 15 **Qiu L**, Wang T, Ge Q, Xu H, Wu Y, Tang Q, Chen K. Circular RNA Signature in Hepatocellular Carcinoma. *J Cancer* 2019; **10**: 3361-3372 [PMID: 31293639 DOI: 10.7150/jca.31243]
- 16 **Yao R**, Zou H, Liao W. Prospect of Circular RNA in Hepatocellular Carcinoma: A Novel Potential Biomarker and Therapeutic Target. *Front Oncol* 2018; **8**: 332 [PMID: 30191143 DOI: 10.3389/fonc.2018.00332]
- 17 **Lyu ZZ**, Li M, Yang MY, Han MH, Yang Z. Exosome-mediated transfer of circRNA563 promoting hepatocellular carcinoma by targeting the microRNA148a-3p/metal-regulatory transcription factor-1 pathway. *World J Gastroenterol* 2023; **29**: 6060-6075 [PMID: 38130740 DOI: 10.3748/wjg.v29.i46.6060]
- 18 **Zhang X**, Chen F, Huang P, Wang X, Zhou K, Zhou C, Yu L, Peng Y, Fan J, Zhou J, Lu Z, Hu J, Wang Z. Exosome-depleted MiR-148a-3p derived from Hepatic Stellate Cells Promotes Tumor Progression via ITGA5/PI3K/Akt Axis in Hepatocellular Carcinoma. *Int J Biol Sci* 2022; **18**: 2249-2260 [PMID: 35414782 DOI: 10.7150/ijbs.66184]
- 19 **Lyu Z**, Yang M, Yang T, Ma M, Yang Z. Metal-Regulatory Transcription Factor-1 Targeted by miR-148a-3p Is Implicated in Human Hepatocellular Carcinoma Progression. *Front Oncol* 2021; **11**: 700649 [PMID: 34660270 DOI: 10.3389/fonc.2021.700649]
- 20 **BioRENDER**. Agreement number PL2696KYM8 and LA2696N8DC. [cited 29 November 2023]. Available from: <https://www.biorender.com/>



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

